Affinage

Showing MAD2L1 — MAD2 is a alias.

MAD2L1

Mitotic spindle assembly checkpoint protein MAD2A · UniProt Q13257

Length
205 aa
Mass
23.5 kDa
Annotated
2026-06-10
49 papers in source corpus 15 papers cited in narrative 15 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MAD2L1 (hsMAD2) is a core component of the mitotic spindle assembly checkpoint (SAC) that monitors the completion of microtubule–kinetochore attachment to prevent premature anaphase onset (PMID:8824189). It localizes to kinetochores after chromosome condensation and disappears from them by metaphase, and antibody-mediated interference with hsMAD2 abolishes mitotic arrest in response to spindle perturbation, establishing it as functionally required for checkpoint enforcement (PMID:8824189). Checkpoint activity depends on its association with MAD1: two leucine zipper domains in hsMAD1 (residues 501–522 and 557–571) mediate binding, and a codon-558 Arg→His polymorphism that weakens this interface impairs mitotic arrest (PMID:12042300). During interphase, both proteins co-localize with nuclear pore complexes rather than with Cdc20 (p55CDC) (PMID:11181178). Loss of MAD2L1 function—through promoter hypermethylation in hepatocellular carcinoma (PMID:15574775) or a Leu84Met missense variant (PMID:20516147)—produces a defective checkpoint, reduced 4N DNA content, and tetraploidy. MAD2L1 transcription is controlled by multiple upstream inputs, including RUNX1 and the ETV6/RUNX1 fusion acting on RUNX1 sites in its promoter (PMID:20190817), BRCA1 (PMID:33158996), and TEAD4 (PMID:36599972), while its abundance is also set post-transcriptionally by mRNA-stabilizing axes including KIFC1/FXR1 (m6A-dependent) (PMID:39387242) and KAT2A-driven RCC2 lactylation–SERBP1 under high glucose (PMID:40145796). Beyond mitosis, MAD2L1 participates in oncogenic circuits: it engages a TYK2/STAT3 positive-feedback loop in B-ALL (PMID:36781502) and binds NANOG to promote its nuclear localization and chemoresistance in lung cancer (PMID:40233918).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1996 High

    Established that human MAD2 is functionally required for the mitotic checkpoint, moving it from a candidate to a defined SAC effector whose loss permits anaphase despite spindle damage.

    Evidence Antibody electroporation into HeLa cells with mitotic-arrest readout plus kinetochore immunofluorescence

    PMID:8824189

    Open questions at the time
    • Molecular partners mediating checkpoint signaling not yet defined
    • Does not address how kinetochore attachment status is sensed
  2. 2001 High

    Identified MAD1 as the partner of MAD2 and revealed an unexpected interphase localization at nuclear pore complexes, distinguishing the MAD1–MAD2 complex from a Cdc20-bound state.

    Evidence Reciprocal co-IP, co-immunofluorescence with NPC markers, and nuclear envelope fractionation in mammalian cells

    PMID:11181178

    Open questions at the time
    • Functional role of NPC association during interphase not established
    • Does not define the structural basis of MAD1–MAD2 binding
  3. 2002 High

    Mapped the MAD1–MAD2 binding interface to two MAD1 leucine zipper domains and linked it directly to checkpoint function via a natural polymorphism that weakens binding.

    Evidence Deletion/mutagenesis of MAD1 leucine zippers, co-IP, and mitotic index/flow cytometry assays

    PMID:12042300

    Open questions at the time
    • Structural geometry of the interaction not resolved
    • Single-lab functional readout
  4. 2010 High

    Demonstrated transcriptional control of MAD2L1 by RUNX1 and its leukemic fusion ETV6/RUNX1, connecting checkpoint gene dosage to aneuploidy and tetraploidy in leukemia.

    Evidence ChIP-validated promoter binding, reporter assays, checkpoint flow cytometry, and karyotyping

    PMID:20190817

    Open questions at the time
    • Whether downregulation drives tumorigenesis in vivo not shown
    • Other promoter regulators not excluded
  5. 2010 Medium

    Showed that a MAD2L1 coding variant (Leu84Met) impairs checkpoint enforcement, providing genetic evidence that MAD2L1 sequence integrity is required for SAC function.

    Evidence Flow cytometry 4N DNA content and mitotic index after nocodazole comparing wild-type vs variant transfection

    PMID:20516147

    Open questions at the time
    • Mechanism by which Leu84Met perturbs MAD2 not defined
    • Single-lab functional assay
  6. 2004 Medium

    Identified epigenetic silencing of MAD2L1 by promoter hypermethylation as a route to checkpoint defects in hepatocellular carcinoma.

    Evidence Promoter cloning/reporter assay, bisulfite sequencing, RT-PCR and western blot in HCC lines

    PMID:15574775

    Open questions at the time
    • Causal demethylation rescue not shown
    • Single tumor type
  7. 2020 High

    Placed MAD2L1 downstream of BRCA1 transcriptionally and showed its loss phenocopies BRCA1 deficiency, linking it to BUBR1 kinetochore recruitment and drug-induced apoptosis.

    Evidence siRNA knockdown, RT-PCR/western, BUBR1 immunofluorescence, apoptosis/cell-cycle flow cytometry, and ex vivo explants

    PMID:33158996

    Open questions at the time
    • Direct BRCA1 promoter occupancy at MAD2L1 not demonstrated
    • Mechanism of BUBR1 dependence not detailed
  8. 2023 Medium

    Established TEAD4 as a positive transcriptional regulator of MAD2L1 driving colorectal cancer growth, validated by epistatic rescue.

    Evidence Luciferase reporter with TEAD4 binding site, siRNA knockdown, and MAD2L1 overexpression rescue of proliferation/migration

    PMID:36599972

    Open questions at the time
    • Direct ChIP occupancy not shown
    • Single lab
  9. 2023 Medium

    Uncovered a non-mitotic oncogenic role: MAD2L1 activates TYK2/STAT3 signaling while STAT3 transcriptionally feeds back on MAD2L1, forming a self-amplifying loop in B-ALL.

    Evidence Co-IP, ChIP, luciferase reporter, siRNA knockdown, and xenograft

    PMID:36781502

    Open questions at the time
    • Direct vs indirect nature of MAD2L1–TYK2 interaction unclear
    • Not independently replicated
  10. 2024 Medium

    Defined a post-transcriptional axis in which KIFC1–FXR1 stabilizes MAD2L1 mRNA in an m6A-dependent manner, with loss driving senescence in sarcoma.

    Evidence Co-IP, mRNA stability assays, m6A analysis, and KIFC1 knockout in vitro and in PDX

    PMID:39387242

    Open questions at the time
    • The m6A reader/writer at MAD2L1 transcripts not identified
    • Single lab
  11. 2025 Medium

    Showed that high-glucose-driven RCC2 lactylation recruits SERBP1 to stabilize MAD2L1 mRNA, coupling metabolic state to MAD2L1 levels in breast cancer.

    Evidence Mass spectrometry of lactylation site, K124 mutagenesis, RIP, mRNA stability, co-IP, inhibitor, and in vivo proliferation

    PMID:40145796

    Open questions at the time
    • Direct SERBP1–MAD2L1 mRNA element not mapped
    • Single lab
  12. 2025 Medium

    Identified MAD2L1 as a NANOG partner promoting NANOG nuclear localization, stemness, and carboplatin resistance in lung cancer.

    Evidence Co-IP, NANOG localization imaging, knockdown/overexpression, viability/stemness assays, and xenograft

    PMID:40233918

    Open questions at the time
    • Structural basis of MAD2L1–NANOG binding unknown
    • Relationship to mitotic function not addressed
  13. 2025 Medium

    Extended MAD2L1 transcriptional control to a non-cancer context, with lncRNA SNHG8 recruiting E2F1 to the MAD2L1 promoter to drive cardiac fibrosis.

    Evidence RIP, ChIP of E2F1 at promoter, gain/loss-of-function, and in vivo SNHG8 knockout cardiac fibrosis model

    PMID:41109373

    Open questions at the time
    • Whether E2F1 directly binds MAD2L1 promoter independent of SNHG8 unclear
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How MAD2L1's canonical SAC function mechanistically intersects with its newly described oncogenic interactions (NANOG, TYK2/STAT3) and the multiple convergent transcriptional/post-transcriptional control inputs remains unresolved.
  • No unified model linking mitotic and non-mitotic roles
  • Structural details of MAD2L1 complexes in human cells not resolved in corpus

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 2 GO:0060089 molecular transducer activity 1
Localization
GO:0005634 nucleus 1 GO:0005635 nuclear envelope 1
Pathway
R-HSA-1640170 Cell Cycle 3
Partners
MAD1L1NANOGSTAT3TYK2
Complex memberships
MAD1-MAD2 complex

Evidence

Reading pass · 15 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 Human MAD2 (hsMAD2) is a necessary component of the mitotic checkpoint in HeLa cells; antibody electroporation experiments demonstrated that blocking hsMAD2 abrogated mitotic arrest in response to spindle perturbation. hsMAD2 localizes to kinetochores after chromosome condensation but is absent from kinetochores at metaphase, consistent with a role in monitoring spindle-kinetochore attachment completion. Antibody electroporation into HeLa cells; immunofluorescence localization Science High 8824189
2001 HsMAD2 associates with HsMAD1 in mammalian cells. During interphase, both HsMAD1 and HsMAD2 co-localize with nuclear pore complexes, as confirmed by co-labeling with nuclear pore complex antibodies and co-purification with enriched nuclear envelope fractions. Association with p55CDC (Cdc20) was not detected in this interphase context. Co-immunoprecipitation; co-immunofluorescence with nuclear pore complex markers; subcellular fractionation and co-purification Journal of Cell Science High 11181178
2002 Two leucine zipper domains in hsMAD1 (amino acids 501–522 and 557–571) are required for its binding to hsMAD2. A coding polymorphism at codon 558 of hsMAD1 (Arg→His) reduces hsMAD1–hsMAD2 interaction and impairs mitotic arrest enforcement, directly linking the MAD1–MAD2 binding interface to spindle checkpoint function. Deletion/mutagenesis of hsMAD1 leucine zipper domains; co-immunoprecipitation; mitotic index / flow cytometry assays The Journal of Biological Chemistry High 12042300
2004 A ~0.5 kb fragment upstream of hsMAD2 functions as a strong promoter. In hepatocellular carcinoma cells, transcriptional silencing of hsMAD2 occurs via hypermethylation of this promoter, resulting in reduced hsMAD2 protein expression and defective mitotic checkpoint. Promoter cloning and reporter assay; bisulfite sequencing / methylation analysis; RT-PCR and western blot in HCC cell lines Cancer Research Medium 15574775
2010 The ETV6/RUNX1 fusion oncogene and wild-type RUNX1 both bind RUNX1 sites in the MAD2L1 promoter, regulating its transcription; E/R expression downregulates MAD2L1 mRNA and protein, attenuates the mitotic checkpoint (reduced 4N DNA content and mitotic index after spindle toxin treatment), and promotes tetraploidy. Promoter-reporter assay; ChIP (RUNX1/E/R binding to MAD2L1 promoter); western blot; flow cytometry mitotic checkpoint assay; karyotyping Oncogene High 20190817
2010 A MAD2L1 missense variant Leu84Met impairs spindle checkpoint function: cells expressing MAD2L1-84Met show reduced 4N DNA content and lower mitotic index upon nocodazole treatment compared with cells expressing wild-type MAD2L1. Flow cytometry (4N DNA content); mitotic index assay after nocodazole treatment; transfection of wild-type vs. variant MAD2L1 Journal of Medical Genetics Medium 20516147
2020 BRCA1 silencing leads to co-depletion of MAD2L1 at both mRNA and protein levels, consistent with MAD2L1 being a transcriptional target of BRCA1. Silencing MAD2L1 alone phenocopies BRCA1 loss by abrogating vinorelbine-induced cell-cycle arrest, BUBR1 kinetochore recruitment, and apoptosis, thereby conferring vinorelbine resistance. siRNA knockdown of BRCA1 and MAD2L1; RT-PCR and western blot; immunofluorescence for BUBR1 kinetochore localization; flow cytometry apoptosis/cell-cycle assay; ex vivo tumor explant apoptosis assay Molecular Cancer Therapeutics High 33158996
2023 TEAD4 binds to a recognition motif in the MAD2L1 promoter region and positively regulates MAD2L1 transcription. TEAD4 silencing suppresses CRC cell proliferation and migration, and this effect can be rescued by MAD2L1 overexpression, placing MAD2L1 downstream of TEAD4 in a growth-regulatory axis. Promoter binding assay (luciferase reporter with TEAD4 binding site); siRNA knockdown; overexpression rescue experiments; proliferation and migration assays Cancer Gene Therapy Medium 36599972
2023 MAD2L1 activates the TYK2/STAT3 signaling pathway (co-immunoprecipitation demonstrated physical interaction), and in turn STAT3 binds directly to the MAD2L1 promoter (ChIP assay) to induce its transcription, forming a positive-feedback loop (MAD2L1/TYK2/STAT3) that promotes B-ALL cell proliferation, migration, and invasion. Co-immunoprecipitation; western blot; luciferase reporter assay; chromatin immunoprecipitation (ChIP); siRNA knockdown; xenograft model Journal of Cancer Research and Clinical Oncology Medium 36781502
2025 MAD2L1 physically interacts with NANOG (co-immunoprecipitation) and facilitates NANOG nuclear localization; MAD2L1 knockdown reduces NANOG expression and nuclear localization, whereas MAD2L1 overexpression increases resistance to carboplatin and stemness markers in lung cancer cells. Co-immunoprecipitation; fluorescence imaging of NANOG nuclear localization; gene knockdown/overexpression; cell viability and stemness assays; in vivo xenograft Cellular Signalling Medium 40233918
2025 KAT2A-mediated lactylation of RCC2 at K124 enables RCC2 to recruit SERBP1, which stabilizes MAD2L1 mRNA; this post-translational modification cascade (high glucose → lactate → KAT2A → RCC2 lactylation → SERBP1 recruitment → MAD2L1 mRNA stabilization) upregulates MAD2L1 and promotes breast cancer cell proliferation. Mass spectrometry identification of lactylation site; mutagenesis of K124; RNA immunoprecipitation (RIP) for SERBP1-MAD2L1 mRNA interaction; mRNA stability assay; co-IP; small-molecule inhibitor blocking RCC2 lactylation; in vitro and in vivo proliferation assays Advanced Science Medium 40145796
2024 KIFC1 interacts with FXR1 (an RNA-binding protein), and this interaction stabilizes MAD2L1 mRNA in an m6A-dependent manner; KIFC1 knockout reduces MAD2L1 mRNA stability and MAD2L1 protein levels, leading to cellular senescence in soft tissue sarcoma cells. Co-immunoprecipitation (KIFC1–FXR1); mRNA stability assay; m6A modification analysis; KIFC1 knockout (in vitro and PDX in vivo); senescence assays Advanced Science Medium 39387242
2025 lncRNA SNHG8 interacts with the transcription factor E2F1 and recruits it to the MAD2L1 promoter, driving MAD2L1 transcription and promoting cardiac fibroblast proliferation/migration and cardiac fibrosis; SNHG8 knockout in mice reduces MAD2L1 protein levels and alleviates fibrosis. RNA immunoprecipitation; ChIP (E2F1 at MAD2L1 promoter); gain- and loss-of-function (siRNA/knockout); western blot; in vivo mouse cardiac fibrosis model International Journal of Biological Macromolecules Medium 41109373
2017 MAD2L1 (mitotic arrest deficient 2-like 1) is a component of the spindle assembly checkpoint (SAC); oxidative stress (H2O2) activates the SAC in mouse zygotes as shown by increased MAD2L1 immunofluorescence signal, resulting in a prometaphase/metaphase delay during first cleavage. Immunofluorescence staining for MAD2L1 and TTK in H2O2-treated mouse zygotes; time-course monitoring of H3S10P as prometaphase/metaphase marker Oxidative Medicine and Cellular Longevity Low 29147457
2042 MAD2L1 knockdown in hepatoblastoma cells inhibits proliferation, migration, and invasion, and MAD2L1 promotes cell cycle progression through regulation of E2F transcription factor activity (western blot/cell cycle analysis). siRNA knockdown; CCK-8 proliferation assay; migration/invasion assays; western blot for E2F pathway components; cell cycle analysis Frontiers in Oncology Low 40231267

Source papers

Stage 0 corpus · 49 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1996 Identification of a human mitotic checkpoint gene: hsMAD2. Science (New York, N.Y.) 526 8824189
2001 Mitotic checkpoint proteins HsMAD1 and HsMAD2 are associated with nuclear pore complexes in interphase. Journal of cell science 162 11181178
1999 Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 105 10439037
2001 Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. International journal of cancer 86 11400114
1999 Mutational inactivation of mitotic checkpoint genes, hsMAD2 and hBUB1, is rare in sporadic digestive tract cancers. Japanese journal of cancer research : Gann 84 10543255
2017 MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 73 28609841
2000 Expression and mutational analyses of the human MAD2L1 gene in breast cancer cells. Genes, chromosomes & cancer 73 11066082
2001 Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Japanese journal of cancer research : Gann 52 11572763
2019 miR-30a-3p Targets MAD2L1 and Regulates Proliferation of Gastric Cancer Cells. OncoTargets and therapy 51 31908496
2017 Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma. eLife 50 28318489
2007 Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma. Cancer letters 48 17498870
2010 Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer. Journal of medical genetics 42 20516147
2002 Characterization of regions in hsMAD1 needed for binding hsMAD2. A polymorphic change in an hsMAD1 leucine zipper affects MAD1-MAD2 interaction and spindle checkpoint function. The Journal of biological chemistry 39 12042300
2004 Transcriptional abnormality of the hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis. Cancer research 38 15574775
2008 Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)) 27 18691855
2007 APC inactivation associates with abnormal mitosis completion and concomitant BUB1B/MAD2L1 up-regulation. Gastroenterology 27 17570218
2020 miR-139-5p Inhibits Lung Adenocarcinoma Cell Proliferation, Migration, and Invasion by Targeting MAD2L1. Computational and mathematical methods in medicine 26 33204298
2025 High Sugar Induced RCC2 Lactylation Drives Breast Cancer Tumorigenicity Through Upregulating MAD2L1. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 23 40145796
2009 Expression of mitotic checkpoint proteins BUB1B and MAD2L1 in salivary duct carcinomas. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 22 20040022
2015 MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk of colorectal cancer. Scientific reports 21 26183163
2023 MAD2L1 is transcriptionally regulated by TEAD4 and promotes cell proliferation and migration in colorectal cancer. Cancer gene therapy 20 36599972
2022 Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy. BMC urology 16 35305591
2020 BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. Molecular cancer therapeutics 16 33158996
2023 Potential Signature Therapeutic Biomarkers TOP2A, MAD2L1, and CDK1 in Colorectal Cancer: A Systems Biomedicine-Based Approach. Biochemical genetics 15 37884851
2010 ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1. Oncogene 15 20190817
2017 Pathological significance of MAD2L1 in breast cancer: an immunohistochemical study and meta analysis. International journal of clinical and experimental pathology 13 31966791
2017 Oxidative Stress Delays Prometaphase/Metaphase of the First Cleavage in Mouse Zygotes via the MAD2L1-Mediated Spindle Assembly Checkpoint. Oxidative medicine and cellular longevity 12 29147457
2024 Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis. Scientific reports 11 38698201
2021 Bioinformatics prediction and experimental verification identify MAD2L1 and CCNB2 as diagnostic biomarkers of rhabdomyosarcoma. Cancer cell international 10 34838000
2022 Targeting of MAD2L1 by miR-515-5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells. Cell biology international 8 35143103
2022 Inhibition of MAD2L1 Mediates Pulmonary Fibrosis through Impairment of Mitochondrial Function and Induction of Cell Senescence. Canadian respiratory journal 7 36247080
2021 MAD2L1 Functions As a Novel Diagnostic and Predictive Biomarker in Cholangiocarcinoma. Genetic testing and molecular biomarkers 7 34788140
2024 Targeting KIFC1 Promotes Senescence in Soft Tissue Sarcoma via FXR1-Dependent Regulation of MAD2L1 mRNA Stability. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 6 39387242
2025 MAD2L1-mediated NANOG nuclear translocation: A critical factor in lung cancer chemoresistance. Cellular signalling 4 40233918
2023 Maternal genetic polymorphisms in the major mitotic checkpoint genes MAD1L1 and MAD2L1 associated with the risk of survival in abnormal chromosomal fetuses. Frontiers in genetics 4 37007941
2021 [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 4 34728029
2019 A Study of the Mechanism of Binding between Neratinib and MAD2L1 Based on Molecular Simulation and Multi-spectroscopy Methods. Current pharmaceutical design 3 31696805
2011 HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma. Pediatric surgery international 2 21046120
2025 Identification of MAD2L1 as a novel biomarker for hepatoblastoma through bioinformatics and machine learning approaches. Frontiers in oncology 1 40231267
2024 BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma. Cancer gene therapy 1 39300217
2023 Retracted: miR-139-5p Inhibits Lung Adenocarcinoma Cell Proliferation, Migration, and Invasion by Targeting MAD2L1. Computational and mathematical methods in medicine 1 37811302
2022 Circ_0031242 regulates the functional properties of hepatocellular carcinoma cells through the miR-944/MAD2L1 axis. Histology and histopathology 1 36125054
2026 The MAD2L1-FOXM1 axis negatively regulates CD4⁺ T cell and macrophages infiltration in lung adenocarcinoma. Discover oncology 0 41533300
2026 CCNA2, MAD2L1, AURKA, and PTTG1 promote proliferation and migration in hepatocellular carcinoma. BMC gastroenterology 0 42210102
2025 Investigating the molecular mechanisms, drug prediction, and validation of CCNA2 and MAD2L1 in esophageal squamous cell carcinoma based on bioinformatics. BMC medical genomics 0 40598454
2025 LncRNA SNHG8 promotes myocardial fibrosis by binding to E2F1 to induce MAD2L1 transcription. International journal of biological macromolecules 0 41109373
2025 Bioinformatics and In Vitro/In Vivo Experiments Identify MAD2L1 as an m6A-Associated Biomarker Promoting Oral Squamous Cell Carcinoma Progression. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 0 41320992
2025 Radiotherapy and precision medicine's role in molecular alterations during chromosomal division: The influence of MB, TP53, CENPA, BUB1B, MAD2L1, ZWINT expression and noncoding RNAs in oral cancer. Biochemistry and biophysics reports 0 41378098
2023 The positive feedback loop of MAD2L1/TYK2/STAT3 induces progression in B-cell acute lymphoblastic leukaemia. Journal of cancer research and clinical oncology 0 36781502

Missed literature

Know a paper Affinage missed for MAD2L1? Flag it for the maintainers and the community.

No submissions yet.